Potential of hTERT mRNA for the management of advanced head and neck squamous cell carcinoma.
European Archives of Oto-Rhino-Laryngology · 2026
DOI: 10.1007/s00405-026-10477-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2026. Verfasst von Blanca Pilar Galindo Torres und 5 weiteren Autor:innen. Beteiligte Einrichtung: Servicio Otorrinolaringología, Hospital Universitario de Burgos, Burgos, Spain. bgalindot@saludcastillayleon.es. Hauptthemen laut MEDLINE: Telomerase, RNA, Messenger, Head and Neck Neoplasms, Carcinoma, Squamous Cell. Die Arbeit nennt 57 Literaturangaben. Gefördert von: Fundación Burgos por Investigación de la Salud.
Abstract (Originalsprache)
Purpose hTERT messenger RNA (hTERT mRNA) has been detected in peripheral blood of different cancer patients and its elevation seems related to clinicopathological parameters and treatment efficacy. The objectives are analyzing if hTERT mRNA levels are increased in cancer patients, detecting it they change after treatment and determining if they could be useful in disease monitoring.
Methods
A prospective, analytical, case-control study was conducted, in which peripheral blood of 37 head and neck squamous cell cancer patients and 30 healthy donors were obtained. hTERT mRNA expression levels were determined by PCR-RT. Follow-up of cancer patients was carried out during one year with blood extractions at 7 days for surgical patients, and 1, 2, 6 and 12 months after finishing treatment for all patients. Results hTERT mRNA expression levels were elevated in plasma of cancer patients (0,75) compared to controls (0,5) ( p = 0.003). Patients in more advanced stages had higher hTERT mRNA levels ( p = 0.008). hTERT mRNA levels during follow-up did not change significantly at the different time points but showed a tendency to decrease, comparing treatment responders with tumour persistence patients. An early decrease of hTERT mRNA levels was observed in the five cured patients who underwent surgery.
Conclusions
Detection of plasma hTERT mRNA after surgery might help to identify patients with better prognosis. Quantitation of plasma hTERT mRNA could be a complementary tool for diagnosis, but still further studies are needed to clarify the role and causes of variable circulating hTERT mRNA levels for prognosis and follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio Otorrinolaringología, Hospital Universitario de Burgos, Burgos, Spain. bgalindot@saludcastillayleon.es.
- Otolaryngology Department, block F, 6th floor Av. Islas Baleares, 3, Burgos, 09006, Spain. bgalindot@saludcastillayleon.es.
- Fundación Burgos por la Investigación de la Salud, Hospital Universitario de Burgos, Burgos, Spain.
- Servicio Anatomía Patológica, Hospital Universitario de Burgos, Burgos, Spain.
- Servicio Otorrinolaringología, Hospital Universitario Miguel Servet, Zaragoza, Spain.
- Servicio Oncología Médica, Hospital Universitario de Burgos, Burgos, Spain.
Förderung
- Fundación Burgos por Investigación de la Salud
Zitieren
APA
Galindo Torres, B. P., Alcaraz Ortega, R., Saiz López, P., Adiego Leza, M. I., García Girón, C., & Grijalba Uche, M. V. (2026). Potential of hTERT mRNA for the management of advanced head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-026-10477-5
Vancouver
Galindo Torres BP, Alcaraz Ortega R, Saiz López P, Adiego Leza MI, García Girón C, Grijalba Uche MV. Potential of hTERT mRNA for the management of advanced head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology. 2026. doi:10.1007/s00405-026-10477-5
BibTeX
@article{GalindoTorres2026,
author = {Galindo Torres, Blanca Pilar and Alcaraz Ortega, Raquel and Saiz López, Patricia and Adiego Leza, María Isabel and García Girón, Carlos and Grijalba Uche, Miguel Víctor},
title = {Potential of hTERT mRNA for the management of advanced head and neck squamous cell carcinoma},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2026},
doi = {10.1007/s00405-026-10477-5}
}
EUVIMED